Clostridium butyricum M588 (Miyarisan)
- Generic Name
- Clostridium butyricum M588 (Miyarisan)
PD1 Inhibitors Combined With Clostridium Butyricum for Urothelial Carcinoma
Phase 2
Recruiting
- Conditions
- Bladder (Urothelial, Transitional Cell) Cancer
- Interventions
- First Posted Date
- 2024-11-20
- Last Posted Date
- 2024-11-20
- Target Recruit Count
- 60
- Registration Number
- NCT06696742
- Locations
- 🇨🇳
The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
Induction Chemotherapy Combined With Neoadjuvant Immunotherapy for MSS Colon Cancer
Phase 2
Recruiting
- Conditions
- Colon Neoplasm
- Interventions
- Procedure: ColectomyDrug: Anti-PD-L1 Monoclonal Antibody
- First Posted Date
- 2023-06-22
- Last Posted Date
- 2023-08-08
- Lead Sponsor
- Second Affiliated Hospital, School of Medicine, Zhejiang University
- Target Recruit Count
- 100
- Registration Number
- NCT05914389
- Locations
- 🇨🇳
Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Effect of Clostridium Butyricum in Treating Irritable Bowel Syndrome
Phase 4
- Conditions
- Effect of Clostridium Butyricum in Treating Irritable Bowel Syndrome
- Interventions
- Drug: placebo
- First Posted Date
- 2015-11-25
- Last Posted Date
- 2016-05-17
- Lead Sponsor
- Shandong University
- Target Recruit Count
- 300
- Registration Number
- NCT02614963
- Locations
- 🇨🇳
Department of Gastroenterology, Qilu Hospital, Shandong University, Jinan, Shandong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath